NightHawk Biosciences (NYSE:NHWK) Share Price Passes Below Two Hundred Day Moving Average of $0.99

Shares of NightHawk Biosciences, Inc. (NYSE:NHWK – Get Rating) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.99 and traded as low as $0.77. NightHawk Biosciences shares last traded at $0.78, with a volume of 113,286 shares trading hands.

Analysts Set New Price Targets

Separately, Maxim Group lowered shares of NightHawk Biosciences from a “buy” rating to a “hold” rating in a report on Monday, April 3rd.

NightHawk Biosciences Stock Down 1.6 %

The company has a market cap of $20.25 million, a price-to-earnings ratio of -0.42 and a beta of 0.50. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $0.78 and its 200-day moving average price is $0.99.

NightHawk Biosciences (NYSE:NHWK – Get Rating) last announced its quarterly earnings results on Friday, March 31st. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.60 million. NightHawk Biosciences had a negative net margin of 693.37% and a negative return on equity of 61.62%. Sell-side analysts predict that NightHawk Biosciences, Inc. will post -1.31 earnings per share for the current year.

Institutional Investors Weigh In On NightHawk Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. bought a new stake in NightHawk Biosciences during the 3rd quarter worth about $1,898,000. BlackRock Inc. acquired a new position in shares of NightHawk Biosciences during the 3rd quarter worth approximately $802,000. State Street Corp acquired a new position in shares of NightHawk Biosciences during the 3rd quarter worth approximately $178,000. Dimensional Fund Advisors LP acquired a new position in shares of NightHawk Biosciences during the 3rd quarter worth approximately $160,000. Finally, Millennium Management LLC acquired a new position in shares of NightHawk Biosciences during the 4th quarter worth approximately $54,000. 9.52% of the stock is owned by institutional investors.

About NightHawk Biosciences

(Get Rating)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.